DMK Pharma, a clinical-stage biotechnology company, focuses on developing treatments for Opioid Use Disorder (OUD) and other neuro-based diseases. Their experimental drug, DPI-125, aims to effectively treat morphine withdrawal in an animal experiment. The drug behaves like the body's own opioids, reducing common side effects and abuse potential associated with traditional opioid medications. In 2023, DMK Pharmaceuticals was acquired by Adamis Pharmaceuticals, though the terms of the transaction were not disclosed.